Chimeric anti-tumor necrosis factor-α monoclonal antibody treatment of patients with rheumatoid arthritis receiving methotrexate therapy

Journal of Rheumatology

Volumn 27, Issue 4, 2000, Pages 841-850

  Kavanaugh, Arthur ^a   St Clair, E William ^b   McCune, W Joseph ^b   Braakman, Tanja ^b   Lipsky, Peter ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b NONE

Author keywords

Infliximab; Rheumatoid arthritis; Tumor necrosis factor DMARD methotrexate

Indexed keywords

ANTINUCLEAR ANTIBODY; CHIMERIC ANTIBODY; CORTICOSTEROID; DNA ANTIBODY; DOUBLE STRANDED DNA; INFLIXIMAB; METHOTREXATE; PLACEBO; PREDNISONE; TUMOR NECROSIS FACTOR ALPHA ANTIBODY;

ADULT; ARTICLE; CELLULITIS; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE ACTIVITY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG HALF LIFE; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HEADACHE; HUMAN; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RASH; RHEUMATOID ARTHRITIS; VERTIGO;

ADULT; ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; AUTOANTIBODIES; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; METHOTREXATE; MIDDLE AGED; PILOT PROJECTS; RECOMBINANT FUSION PROTEINS; SEVERITY OF ILLNESS INDEX; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0034039605     PISSN: 0315162X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (27)

1. Buchan G, Barrett K, Turner M, Chantry D, Maini RN, Feldmann M. Interleukin-1 and tumor necrosis factor mRNA expression in rheumatoid arthritis: prolonged production of IL-1a. Clin Exp Immunol 1988;73:449-55.
2. Firestein G, Alvaro-Garcia JM, Maki R. Quantitative analysis of cytokine gene expression in rheumatoid arthritis. J Immunol 1990;144:3347-53.
3. Saxne T, Palladino MA, Heinegard D, Talal N, Wolheim FA. Detection of tumor necrosis factor-α, but no tumor necrosis factor-β in rheumatoid arthritis synovial fluid and serum. Arthritis Rheum 1988;31:1041-5.
4. Feldmann M, Brennan FM, Maini RN. Role of cytokines in rheumatoid arthritis. Ann Rev Immunol 1996;14:397-440.
5. Maini RN, Elliot MJ, Brennan FM, et al. Monoclonal anti-TNF antibody as a probe of pathogenesis and therapy of rheumatoid disease. Immunol Rev 1995;144:195-222.
6. Shingu M, Nagai Y, Isayama T, Naono T, Nobunaga M, Nagai Y. The effects of cytokines on metalloproteinase inhibitors (TIMP) and collagenase production by human chondrocytes and TIMP production by synovial cells and endothelial cells. Clin Exp Immunol 1992;94:145-9.
7. Ahmadzadeh N, Shigu M, Nobunaga M. The effects of recombinant tumor necrosis factor-alpha on superoxide and metalloproteinase production by synovial cells and chondrocytes. Clin Exp Rheumatol 1990;8:387-91.
8. Beckham JC, Caldwell DS, Peterson BL. Disease severity in rheumatoid arthritis: relationships of plasma tumor necrosis factor-alpha, soluble interleukin 2-receptor, soluble CD4/CD8 ratio, neopterin, and fibrin D-dimer to traditional severity and functional measures. J Clin Immunol 1993;12:353-61.
9. Moser RB, Schleiffenbaum B, Groscurth P, Fehr J. Interleukin I and tumor necrosis factor stimulate human vascular endothelial cells to promote transendothelial neutrophil passage. J Clin Invest 1989;83:444-55.
10. Keffer J, Probert L, Cazlaris H, et al. Transgenic mice expressing human tumour necrosis factor: a predictive genetic model of arthritis. EMBO J 1991;10:4025-31.
11. Williams RO, Feldmann M, Maini RN. Anti-tumour necrosis factor ameliorates joint disease in murine collagen-induced arthritis. Proc Natl Acad Sci USA 1992;89:9784-8.
12. Elliott MJ, Maini RN, Feldmann M, et al. Treatment of rheumatoid arthritis with chimeric monoclonal antibodies to tumor necrosis factor α. Arthritis Rheum 1993;12:1681-90.
13. Elliott MJ, Maini RN, Feldmann M, et al. Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor α (cA2) versus placebo in rheumatoid arthritis. Lancet 1994;344:1105-10.
14. Maini RN, Breedveld FC, Kalden JR, et al. Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor α monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis. Arthritis Rheum 1998;41:1552-63.
15. Arnett FC, Edworthy SM, Bloch DA, et al. American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988;31:315-24.
16. Hochberg MC, Chang RW, Dwosh I, Lindsey S, Pincus T, Wolfe F. The American College of Rheumatology 1991 revised criteria for the classification of global functional status in RA. Arthritis Rheum 1992;35:498-502
17. Knight DM, Trinh H, Le J, et al. Construction and initial characterization of a mouse-human chimeric anti-TNF antibody. Mol Immunol 1993;30:1443-53.
18. LoBuglio A, Wheeler R, Trang J, et al. Mouse/human chimeric monoclonal antibody in man: kinetics and immune responses. Proc Natl Acad Sci USA 1989;86:4220-24.
19. Fries JF, Spitz PW, Young DY. The dimensions of health outcomes: The Health Assessment Questionnaire disability and pain scales. J Rheumatol 1982;9:789-93.
20. Felson DT, Anderson JJ, Boers M, et al. The American College of Rheumatology preliminary core set of disease activity measures for rheumatoid arthritis clinical trials. Arthritis Rheum 1993;36:729-40.
21. Tan EM, Feltkamp TEW, Smolen JS, et al. Range of antinuclear antibodies in "healthy" individuals. Arthritis Rheum 1997; 40:1601-11.
22. Moreland LW, Baumgartner SW, Schiff MH, et al. Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)-Fc fusion protein. N Engl J Med 1997;337:141-7.
23. Weinblatt ME, Kremer JM, Bankhurst AD, et al. A trial of etanercept, a recombinant tumor necrosis factor receptor:Fc fusion protein in patients with rheumatoid arthritis receiving methotrexate. N Engl J Med 1999;340:253-9.
24. Moreland LW, Schiff MH, Baumgartner SW, et al. Etanercept therapy in rheumatoid arthritis: a randomized, controlled trial. Ann Intern Med 1999;130:478-86.
25. Havell EA. Evidence that tumour necrosis factor has an important role in antibacterial resistance. J Immunol 1989;143:2894-9.
26. Pfeffer K, Matsuyama T, Kundig TM, et al. Mice deficient for the 55kd tumour necrosis factor receptor are resistant to endotoxic shock, yet succumb to L. monocytogenes infection. Cell 1993;73:457-67.
27. Boerbooms AM, Kerstens PJ, van Loenhout JW, Mulder J, van de Putte LB. Infections during low-dose MTX treatment in rheumatoid arthritis. Semin Arthritis Rheum 1995;24:411-21.